Skip to the article

Healthy Pound research desk

Peptide compounding: the policy, the product and the promise

A conditional access policy and a company's future service raise separate questions about what patients could receive.

Healthy Pound Editorial Team · Published · Sources checked

At our October 30 check in US/Eastern time, the Federal Register public-inspection record still scheduled publication for October 30; we had not verified a published notice. It describes a draft, nonbinding 503A compounding policy during rulemaking, without establishing an effective date.[2]

The notice does not establish permanent list inclusion or a new 503B permission. It describes enforcement discretion, not FDA approval of a finished medicine.[2]

Preparations

All conditions apply; routes are not treatment instructions.[1]

Exact formDescribed route
BPC-157 acetateSubcutaneous, intramuscular, oral, topical
TB-500 acetateSubcutaneous or intramuscular injection
Epitalon acetateSubcutaneous or intramuscular injection; intermittent courses
Semax free baseIntranasal
KPV acetateTopical or oral
MOTS-c acetateSubcutaneous or intramuscular injection

Ten conditions

  1. Appendix A substance.
  2. Appendix B identity and route limitations.
  3. Section 510-registered source facility; valid certificate of analysis (COA) testing identity, purity, potency and contaminants per Appendix B.
  4. Original manufacturer: FDA registration, current good manufacturing practice (CGMP), other FD&C requirements and physical address on COA; registered intermediaries document manufacturer/COA validation.
  5. Report products, serious adverse events regardless of suspected causation, and quality issues to FDA and compounding/destination States; patient reporting instructions on labeling.
  6. Label: “This is a compounded drug product. Not for resale.”
  7. One active ingredient, listed in Appendix A.
  8. Oral formulations: document adequate human bioavailability of the specific supplied formulation.
  9. Only FDA 510(k)-cleared syringes as delivery devices co-packaged with or containing the drug.
  10. Other applicable FD&C requirements, including sanitary conditions and patient-specific prescriptions.[1]

The finished product still matters

FDA explains that compounded medicines do not undergo its premarket verification of safety, effectiveness or quality. They are also different from FDA-approved generics. Compounding can meet a medical need an approved product cannot, but poor preparation can introduce contamination or the wrong amount of active ingredient.[4]

Quality standards depend on the setting. FDA says section 503A finished-drug compounding that meets its conditions is exempt from CGMP requirements; outsourcing facilities are subject to them. The federal prohibition on insanitary conditions applies in every setting.[4]

A preview is not a dispensing record

Hims & Hers announced a Peptides+ preview and waitlist on October 29. Its planned menu names sermorelin, glutathione, B12, NAD+ and L-carnitine; BPC-157 and TB-500 would follow when allowable. The menu includes nonpeptide therapies.[3]

The company describes independent prescribers, licensed pharmacies and ongoing support, subject to eligibility. These plans do not verify launch, dispensing, specific preparations or clinical benefit. Its forward-looking disclosure identifies uncertainty around rollout, safety evidence, manufacturing and regulatory decisions.[3]

Reader questions

What would I actually receive?

Ask for the drug, formulation and dispensing pharmacy before treating a service name as a product description. FDA warns that online customers may not know who compounded their medicine or whether the compounder meets appropriate standards. A platform's branding does not answer that sourcing question.[4]

Can this establish a recovery benefit?

Hims acknowledges limited published studies and says it draws on clinical experience from the past decade. That describes the company's evidence base; it does not supply a controlled comparison for a specific treatment. This explainer verifies the announcement, not a treatment's efficacy.[3]

What should readers watch next?

The notice invites comments for two weeks after actual publication and says HHS may revisit the policy for a safety signal or quality issue. Check the official record before relying on the schedule. Do not turn the scheduled date into a fixed comment deadline or guaranteed access date.[2]

Sources

  1. HHS policy · HHS · Checked
  2. Federal Register notice · Federal Register · Checked
  3. Peptides+ announcement · Hims & Hers · Checked
  4. Compounding questions and answers · FDA · Checked